Literature DB >> 27418649

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Catherine C Coombs1, David A Sallman2, Sean M Devlin3, Shweta Dixit4, Abhinita Mohanty5, Kristina Knapp4, Najla H Al Ali2, Jeffrey E Lancet2, Alan F List2, Rami S Komrokji2, Eric Padron2, Maria E Arcila5, Virginia M Klimek1, Marcel R M van den Brink6, Martin S Tallman1,7, Ross L Levine1,4, Raajit K Rampal8, Franck Rapaport1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27418649      PMCID: PMC5394875          DOI: 10.3324/haematol.2016.148999

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

2.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors:  D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal:  Leukemia       Date:  2015-10-30       Impact factor: 11.528

3.  DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Authors:  K H Metzeler; A Walker; S Geyer; R Garzon; R B Klisovic; C D Bloomfield; W Blum; G Marcucci
Journal:  Leukemia       Date:  2011-11-29       Impact factor: 11.528

4.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

5.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

6.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

7.  Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.

Authors:  Donavan T Cheng; Janice Cheng; Talia N Mitchell; Aijazuddin Syed; Ahmet Zehir; Nana Yaa T Mensah; Alifya Oultache; Khedoudja Nafa; Ross L Levine; Maria E Arcila; Michael F Berger; Cyrus V Hedvat
Journal:  J Mol Diagn       Date:  2014-07-10       Impact factor: 5.568

8.  Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.

Authors:  Ashkan Emadi; Rawan Faramand; Brandon Carter-Cooper; Seda Tolu; Laurie A Ford; Rena G Lapidus; Meir Wetzler; Eunice S Wang; Arash Etemadi; Elizabeth A Griffiths
Journal:  Am J Hematol       Date:  2015-02-27       Impact factor: 13.265

9.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

10.  Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.

Authors:  Courtney D DiNardo; Keyur P Patel; Guillermo Garcia-Manero; Rajyalakshmi Luthra; Sherry Pierce; Gautam Borthakur; Elias Jabbour; Tapan Kadia; Naveen Pemmaraju; Marina Konopleva; Stefan Faderl; Jorge Cortes; Hagop M Kantarjian; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2014-02-04
View more
  8 in total

1.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

2.  Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Authors:  Maximilian Stahl; Kamal Menghrajani; Andriy Derkach; Alexander Chan; Wenbin Xiao; Jacob Glass; Amber C King; Anthony F Daniyan; Christopher Famulare; Bernadette M Cuello; Troy Z Horvat; Omar Abdel-Wahab; Ross L Levine; Aaron D Viny; Eytan M Stein; Sheng F Cai; Mikhail Roshal; Martin S Tallman; Aaron D Goldberg
Journal:  Blood Adv       Date:  2021-03-09

3.  Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.

Authors:  Anthony M Hunter; Rami S Komrokji; Seongseok Yun; Najla Al Ali; Onyee Chan; Jinming Song; Mohammad Hussaini; Chetasi Talati; Kendra L Sweet; Jeffrey E Lancet; Eric Padron; Alan F List; David A Sallman
Journal:  Blood Adv       Date:  2021-02-23

4.  A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Authors:  Kirk E Cahill; Yasmin H Karimi; Theodore G Karrison; Nitin Jain; Margaret Green; Howard Weiner; Noreen Fulton; Sabah Kadri; Lucy A Godley; Andrew S Artz; Hongtao Liu; Michael J Thirman; Michelle M Le Beau; Megan E McNerney; Jeremy Segal; Richard A Larson; Wendy Stock; Olatoyosi Odenike
Journal:  Blood Adv       Date:  2020-02-25

5.  Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.

Authors:  Gerwin Huls; Dana A Chitu; Thomas Pabst; Saskia K Klein; Georg Stussi; Laimonas Griskevicius; Peter J M Valk; Jacqueline Cloos; Arjan A van de Loosdrecht; Dimitri Breems; Danielle van Lammeren-Venema; Isabelle van Zeventer; Rinske Boersma; Mojca Jongen-Lavrencic; Martin Fehr; Mels Hoogendoorn; Markus G Manz; Maaike Söhne; Rien van Marwijk Kooy; Dries Deeren; Marjolein W M van der Poel; Marie Cecile Legdeur; Lidwine Tick; Yves Chalandon; Emanuele Ammatuna; Sabine Blum; Bob Löwenberg; Gert J Ossenkoppele
Journal:  Blood Adv       Date:  2020-09-22

6.  DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.

Authors:  Heidi L Casellas Román; Kartika Venugopal; Yang Feng; Daniil E Shabashvili; Luisa M Posada; Jianping Li; Olga A Guryanova
Journal:  Leuk Res       Date:  2020-05-13       Impact factor: 3.156

Review 7.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

Review 8.  Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Authors:  Andrea Kuendgen; Catharina Müller-Thomas; Michael Lauseker; Torsten Haferlach; Petra Urbaniak; Thomas Schroeder; Carolin Brings; Michael Wulfert; Manja Meggendorfer; Barbara Hildebrandt; Beate Betz; Brigitte Royer-Pokora; Norbert Gattermann; Rainer Haas; Ulrich Germing; Katharina S Götze
Journal:  Oncotarget       Date:  2018-06-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.